Press Releases

Landmark Longitudinal Study in Over 1,000 Transplant Patients Confirms AlloSure More Accurately Measures Organ Health SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and

Eledon to use AlloSure to help assess the efficacy of AT-1501 in the prevention of rejection in Eledon’s upcoming renal transplantation trials SOUTH SAN FRANCISCO, Calif. and IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today

AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically

Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and

False Advertising Lawsuit Against Natera is Set to Go to Trial CareDx Plans to Appeal Recent Ruling in Patent Case SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and

AlloSeq to be featured in 8 scientific abstracts at ASHI conference SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value

Torres Adds Expertise in Regenerative Medicine and Organ Procurement to the CareDx Board SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,

CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium SOUTH SAN FRANCISCO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,